CMS identifies billing codes for Eli Lilly's COVID-19 antibody therapy

CMS published specific codes for billing Medicare for Eli Lilly's COVID-19 antibody cocktail.

The FDA granted emergency use authorization Feb. 9 to the antibody cocktail, a combination of antibodies bamlanivimab and etesevimab. 

The agency granted emergency use authorization to bamlanivimab Nov. 9. The new approval is based on phase 3 trial data that showed that administering bamlanivimab in combination with etesevimab reduced the risk of COVID-19 hospitalization and death by 70 percent.

The codes for the antibody cocktail, published Feb. 18, are Q0245 and M0245, with the latter assigned to a 2100 mg injection and the former assigned to an intravenous infusion and post-administration monitoring.

More articles on healthcare finance:
House Democrats' COVID-19 relief bill: 8 things to know
CMS cuts payments to 774 hospitals over patient complications
5 hospitals, health systems that recently tapped RCM partners

 

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Whitepapers

Featured Webinars